作为人类与数字世界交互的视觉窗口，"分辨率"在显示技术的迭代升级中不断突破精度极限。而今，在 AI技术的催化下，"超分辨率技术"悄然发展，正通过智能算法重构图像细节，让我们的"视界"更清晰。 在影像增强与细节重建方面，亿达科创将通过超分辨率技术，以及卷积神经网络（CNN）、残差网络 （ResNet）或生成对抗网络（GAN）等深度学习模型，对医学影像进行高质量重建，从低分辨率图像 中学习到高频细节，提升图像分辨率与清晰度，解析微小病变细节。 智能病灶识别与辅助诊断方面，基于深度学习的图像识别算法，亿达科创自研的智能诊断辅助系统将实 现病灶区域的自动检测与标注。基于规则的推理引擎或基于机器学习的预测模型，将图像识别结果与医 学知识库中的信息进行融合，生成结构化诊断建议报告，辅助医生快速定位关键病变特征，减少人工阅 片时间。 医疗级交互界面与数据安全体系方面，智能诊断辅助系统将通过专业影像处理界面，提升临床操作效 率；并通过隐私保护机制，实现影像数据全链路加密，确保敏感医疗数据零泄露风险。 数据驱动诊疗，技术普惠民生。未来，亿达科创自研的"实现超分辨率特征引导图像识别的智能诊断辅 助系统"解决方案将应用于早期癌症筛 ...

2025.4.25 卫宁AI规划及进展 AI重新定义医疗 医生手工操作 机械工具（听诊器、手术刀） 纸质病历、手工计算（如药物剂量） | 基础实验设备（显微镜） 主要依赖个人经验与 物理工具进行诊断 手术依赖手工操作 信息存储于纸质档案 Patterns Tool-Dependent 规则驱动的流程自动化 电子病历（EMR） | 医院信息管理系统（HIS）| 医学影像存档与通信系统（PACS）等 作者：Erich Gamma等 1994年出版 VS Code 之父 率领团队开发Visual Studio Code （一个轻量级的Web集成开发环境） Software Patterns AI Agentic 目标驱动的自主决策与协作 大语言模型 | 多模态AI | 手术机器人等 • Finding Appropriate Objects 寻找合适对象 • Determining Object Granularity 确定对象粒度 • Sepcifying Object Interfaces 指定对象接口 • Sepcifying Object Implementations 指定对象实现 • Putting R ...

Core Insights - The summit focused on new career opportunities and transformation paths in the context of AI, low-altitude economy, and green energy, emphasizing the importance of aligning personal growth with industry trends [1][22] Group 1: Regional Industry Advantages - Chengdu has established a differentiated advantage in sectors like chip design (annual scale exceeding 30 billion), AI algorithms (25% of high-paying positions), and medical technology (AI imaging penetration rate of 35%), positioning itself as a hub for technological innovation in Western China [5] - Leading companies in Chengdu's chip sector, such as Huawei HiSilicon and Zhenxin Technology, offer annual salaries ranging from 350,000 to 1.2 million [5] Group 2: Salary Structure Insights - In comparison to Beijing's "olive-shaped" salary distribution, Chengdu exhibits a "pyramid-shaped" structure where 70% of workers are in entry-level positions (8,000-15,000), while only 12% occupy high-paying roles, indicating a need for career advancement through industry positioning and skill enhancement [5] Group 3: Wealth Accumulation Pathways - The summit introduced a five-stage wealth accumulation theory, highlighting the significance of the "golden career period" (ages 29-35) and advocating for diversified asset allocation in high-growth industries, citing examples like Shenzhen's housing prices increasing tenfold in eight years and Huawei's stock compounding growth [5] Group 4: AI and Career Development - The discussion on AI's impact on career paths outlined three stages of AI technology penetration: infrastructure layer (e.g., OpenAI), application tools layer (e.g., Manus AI), and industry transformation layer (e.g., AI-driven supply chain optimization in Chengdu's tea industry) [9][10] - Strategies for career transition included deepening industry chain engagement, empowering traditional industries with AI, and the rise of "super individuals" leveraging AI for creative endeavors [12] Group 5: Enhancing Workplace Competitiveness - The "constant-variable" career evolution model was proposed, emphasizing the identification of personal strengths through assessments and the need for career choices to align with individual values [14] - The summit highlighted that AI serves as an amplifier rather than a replacement, urging professionals to focus on unique human skills that AI cannot replicate, such as empathy and critical thinking [16] Group 6: AI in Job Seeking - Practical applications of AI in job seeking were discussed, including building a career knowledge base, optimizing resumes using AI tools, and managing professional image through social media [18][20] - The summit concluded with a call for individuals to integrate their strengths with market demands to achieve exponential career growth, positioning 2025 as a new starting point rather than an endpoint [22]

华夏时报（www.chinatimes.net.cn）记者 陈岩鹏 北京报道 在国家卫健委"力争2025年底全国90%以上的县域建成紧密型医共体"目标下，AI技术正成为撬动基层医疗资源整 合的战略杠杆。 "国家层面应加快完善医共体建设标准体系，地方政府需建立'一把手'负责的跨部门协调机制，而医疗机构应把握 人工智能技术窗口期。"在第七届中国健康县域大会上，国家医疗健康大数据研究院（宁夏）院长史金龙的讲话揭 开了基层医疗数字化转型的深层逻辑，"医疗大模型不是'取代医生'，而是帮助基层医生突破能力边界的重要工 具。当村医能通过AI获得三甲医院水平的决策支持时，分级诊疗才能真正落地。" 2025年4月26日，北京九华山庄的会场内，"AI"成了最频繁的关键词。台上，专家们用"革命性""颠覆性"形容人工 智能对县域医疗的冲击；台下，来自全国近千家县域医疗机构的负责人举着手机，记录屏幕上飞速滚动的技术方 案——这些曾专属于三甲医院的技术，正通过算法模块向2856个县级行政区"下沉"。而这场大会的主题直击痛 点：县域医共体人工智能生态建设。 数坤科技创始人、董事长毛新生展示的苏州案例中，千万级居民健康档案与AI大模型的碰撞 ...

百度智能驾驶、理想汽车、蚂蚁数科等内地明星企业，以及亿杉医疗科技（新加坡）、应脉医疗科技 （美国）等多家外资企业，共计18家全球知名企业近日落户香港。香港特区政府引进重点企业办公室近 年来累计引进的84家重点企业，未来数年内预期在港投资约500亿港元，创造2万多个就业岗位。在单边 主义、保护主义泛滥的国际经济局势下，成绩来之不易。 香港吸引投资者目光的优势有很多，如区位优势、研发实力、专业服务等，但最大的优势是国家赋予香 港的自由港地位。 面对复杂多变的世界经贸形势，香港坚定不移保持自由港地位，保障资本、货物、信息、人员的自由流 动，坚持简单低税制，致力营造充满活力的创科生态系统，让关注香港的全球投资者吃下了定心丸。中 国（深圳）综合开发研究院与英国智库Z/Yen集团发布的第37期《全球金融中心指数》报告显示，香港 在全球排名第三，且在投资管理、保险业、融资三项位列全球第一。港股市场在今年一季度首次公开募 股融资额度182亿港元，同比增加287%，创下2021年以来的新高。 香港的耐心资本发挥了风向标和稳定器的作用。于2022年设立的香港投资管理有限公司负责管理"香港 增长组合""大湾区投资基金""策略性创科 ...

来源：中国新闻网 图为论坛现场。雷键 摄 中国科学院院士、陆军军医大学第一附属医院病理科主任、金凤实验室主任卞修武表示，金凤智慧病理 中心依赖病理、影像、检验、临床、人工智能等专家资源，依托金凤实验室有组织地开展集中攻关，目 标是促进病理诊断精准化与治疗决策普惠化。金凤实验室将有计划、有步骤地推进金凤智慧病理中心建 设，并发起"千万级泛病种标准化病理数据库计划"，支撑样本和数据模块建设；打造"金凤病理智能标 算平台"，支撑平台和工具模块建设。 金凤实验室副主任徐辉表示，"千万级泛病种标准化病理数据库计划"由金凤实验室联合8家市外医疗机 构、市内12家医疗机构共同发起，将整合人体9大系统、5种主要病理类型疾病数据，建立覆盖病理图 像、诊断报告、临床文本的泛病种病理数据集以及多模态标准化数据集，形成功能强大的数据基座，同 时构建脑肿瘤病理样本及数据全流程标准化体系，为AI诊疗产品研发提供高质量数据资源支持。 此外，"重庆先进病理研究院"和"重庆市医学生物样本数据资源库"在论坛上正式揭牌。(完) 中新网重庆4月18日电 (梁钦卿)以"AI赋能病理·智启健康未来"为主题的智慧病理发展论坛17日在重庆举 行。来自全国病 ...

据介绍，"镜观"是全球首个深度融合大数据、AI技术与医疗资源的消化内镜全场景智能体，由复旦大学 附属中山医院等研发，通过整合超百万例内镜影像，构建消化内镜多模态基础模型，并依托国产自主 AI芯片实现医院端侧安全部署，形成"感知-决策-执行-进化"的完整智能链。 "镜观"可以成为患者的私人医疗顾问，除了一对一详细解读报告、答疑解惑之外，还可以通过知识图谱 及专病数据库，深入解读疾病相关情况，进一步实现预防科普和健康宣传等功能。它可以是医生的"手 术智囊伙伴"，医生可以通过"镜观"搭载的眼动和语音交互功能，在手术中实时获取病灶分析。同 时，"镜观"还能自动生成结构化报告，医生只需要查缺补漏和最终确认，文书时间可至少缩短至 50%。"镜观"还搭载了诊疗规范库，能智能预警操作风险，为基层医生提供三甲级水平的实时指导。 此外，"镜观"还是辅助医院管理决策的"科室大管家"，系统基于国产AI算力平台开发，通过"管理驾驶 舱"进行数据资源整合、智能分析，实现科室运转的精准调控。在安全性方面，做到了"数据不出院"的 安全架构，也使得"镜观"可在基层医院快速部署。据透露，未来三年，该平台计划接入全国300家医疗 机构，培训200 ...

Core Viewpoint - Zhiyun Health (09955) reported a revenue of 3.488 billion RMB for the fiscal year ending December 31, 2024, with a gross profit of 862 million RMB and a stable gross margin of 24.7%, reflecting a year-on-year increase of 0.1 percentage points [1] Financial Performance - The increase in overall gross margin is attributed to the improvement in the gross margin of outpatient solutions, which rose from 14.2% for the year ending December 31, 2023, to 23.1% for the year ending December 31, 2024 [1] - The net profit of the five subsidiaries involved in the divestitures totaled 99.6 million RMB (pre-tax) for the fiscal year ending December 31, 2024 [6] Divestiture Details - On March 30, 2025, Zhiyun Health's subsidiary, Hangzhou Kangsheng Health Management Consulting Co., Ltd., agreed to sell 55% of Zhejiang Qilian Pharmaceutical Co., Ltd. for 33.5164 million RMB [1] - The company also agreed to sell 30% of Jiangsu Xinwange Medical Technology Co., Ltd. for 32 million RMB and 65% of Jiangsu Wandi Biotechnology Co., Ltd. for 3 million RMB [3] - Additionally, 75% of Lianyungang Zhenghe Scientific Instrument Co., Ltd. was sold for 8 million RMB, and 35% of Jiangsu Chengsheng Gene Precision Medical Technology Co., Ltd. was sold for 3 million RMB [4] Strategic Rationale - The divestitures align with the company's long-term strategy focusing on AI-driven SaaS technology advancements and monetizing the P2M (Patient to Manufacturer) pipeline [1] - The decision to divest is driven by strategic and operational considerations, particularly the need to optimize the P2M strategy and integrate AI as part of the company's transformation efforts [4] Market Impact - The five subsidiaries involved in the divestitures are significantly affected by the national medical insurance bureau's procurement policies, which have led to price reductions in their products [5] - The anticipated sixth batch of high-value medical consumables procurement and the eleventh batch of drug procurement by the national medical insurance bureau in 2025 is expected to adversely impact the future revenue, profit, and asset quality of these subsidiaries [5]

涉及总金额6 0 1 . 4 4亿元人民币。 作者 | 私募通 报道 | 决策投资圈 （ID： PEDATAMAX） 清科创业（01945.HK）旗下私募通统计：截至本周五下午，募资、投资、上市和并购共167起事件，涉及总 金额601.44亿人民币。从交易金额来看，本周金额较大事件是：2025年3月27日，华润三九医药股份有限公 司成功受让天士力生物医药产业集团有限公司、天津和悦科技发展合伙企业（有限合伙）、天津康顺科技发 展合伙企业（有限合伙）、天津顺祺科技发展合伙企业（有限合伙）、天津善臻科技发展合伙企业（有限合 伙）等持有的天士力医药集团股份有限公司的28. 0%的股权，作价59.90亿人民币。从交易事件地域分布看， 目前主要分布在广东省、江苏省和浙江省，占比为广东省15.6%，江苏省13.8%，浙江省12 .6%。 更多信息请登录：htt ps://ma x.pe da t a . c n/ 本周新登记股权投资基金管理人共计0家，取消备案登记12家，全年截至目前累计股权投资基金管理人数量 为17家。本周新增备案基金数量为85只，规模总计41 8. 88亿元，本周备案基金募资最多的为南京江宁智慧股 权投 ...

Group 1 - Shenzhen People's Hospital, Shukun Technology, and Huawei have formed a deep collaboration to deploy the DeepSeek-R1 model and the "Shukun Kun" multi-modal healthcare model, enhancing the hospital's medical and research capabilities [3] - The platform equipped with DeepSeek and "Shukun Kun" medical models will provide comprehensive research support, enabling rapid construction of multi-modal databases and offering data analysis tools for researchers [5] - The global first peritoneal dialysis model was launched by Shenzhou Medical and Sun Yat-sen University First Affiliated Hospital, utilizing advanced DHC+DeepSeek dual-engine architecture for precise understanding and processing of complex information in the field [7] Group 2 - Yingxi Intelligent has deployed its first bipedal humanoid robot named "Supervisor" in its AI-driven fully automated drug discovery laboratory, aimed at enhancing laboratory operations [10] - The innovative implantable neurostimulation system by Boruikang has passed the review by the National Medical Products Administration, marking a significant advancement in medical technology [12] - The commercial production base for small nucleic acid drugs by Zhaowei Technology has officially commenced operations, featuring advanced equipment and a total designed capacity of 48 production lines [20] Group 3 - Zhengxu Bio's self-developed base editing drug CS-101 has successfully treated a Malaysian patient with beta-thalassemia, marking another significant achievement in gene editing therapy [23] - The OCT intravascular imaging catheter developed by Weiguang Medical has received registration approval for dual indications, enhancing diagnostic efficiency in coronary and carotid artery diseases [26] - The first platelet-related cell new drug XJ-MK-002 has been granted orphan drug designation by the FDA for treating congenital thrombocytopenia, showcasing innovation in rare disease treatment [28] Group 4 - The new generation PI3Kα inhibitor JYP0035 capsule has received approval for clinical trials, aimed at treating PIK3CA mutated, HR-positive, HER2-negative breast cancer, indicating strong R&D capabilities [30] - The first domestically developed antibacterial fishbone suture line has been approved by the NMPA, representing a breakthrough in surgical materials [43] - The flexible ultrasound probe project led by Suzhou Nolaisheng Technology has been approved as a national key research and development project, highlighting advancements in ultrasound technology [39]